ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -36.44% | -10.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.31% | -17.59% | |||
| Operating Income | 43.31% | 17.59% | |||
| Income Before Tax | 40.67% | 12.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 40.79% | 13.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.79% | 13.11% | |||
| EBIT | 43.31% | 17.59% | |||
| EBITDA | 43.27% | 17.57% | |||
| EPS Basic | 70.61% | 26.61% | |||
| Normalized Basic EPS | 70.55% | 26.35% | |||
| EPS Diluted | 70.61% | 26.61% | |||
| Normalized Diluted EPS | 70.55% | 26.35% | |||
| Average Basic Shares Outstanding | 101.47% | 18.39% | |||
| Average Diluted Shares Outstanding | 101.47% | 18.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||